Becton, Dickinson and Company $BDX Shares Sold by Bahl & Gaynor Inc.

Key Points

• Bahl & Gaynor Inc. reduced its holdings in Becton, Dickinson and Company by 6.7%, selling 5,610 shares, leaving them with 78,018 shares valued at $17.87 million.
• Insider transactions include Director Claire Fraser selling 863 shares at $192.30 each, resulting in a 3.59% decrease in her ownership stake.
• Becton, Dickinson reported $3.68 EPS for the last quarter, surpassing analyst estimates, and has set a guidance of 14.300-14.450 EPS for FY 2025.

Bahl & Gaynor Inc. lessened its holdings in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 6.7% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 78,018 shares of the medical instruments supplier's stock after selling 5,610 shares during the period. Bahl & Gaynor Inc.'s holdings in Becton, Dickinson and Company were worth $17,871,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in BDX. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Becton, Dickinson and Company by 7.9% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 14,136 shares of the medical instruments supplier's stock worth $3,238,000 after buying an additional 1,036 shares during the period. Douglass Winthrop Advisors LLC increased its holdings in shares of Becton, Dickinson and Company by 2.9% in the first quarter. Douglass Winthrop Advisors LLC now owns 435,930 shares of the medical instruments supplier's stock worth $99,854,000 after buying an additional 12,192 shares during the period. AlphaQuest LLC increased its holdings in shares of Becton, Dickinson and Company by 3,563.3% in the first quarter. AlphaQuest LLC now owns 1,099 shares of the medical instruments supplier's stock worth $252,000 after buying an additional 1,069 shares during the period. Van Hulzen Asset Management LLC increased its holdings in shares of Becton, Dickinson and Company by 17,014.2% in the first quarter. Van Hulzen Asset Management LLC now owns 63,836 shares of the medical instruments supplier's stock worth $14,622,000 after buying an additional 63,463 shares during the period. Finally, Allstate Corp increased its holdings in shares of Becton, Dickinson and Company by 16.3% in the first quarter. Allstate Corp now owns 10,101 shares of the medical instruments supplier's stock worth $2,314,000 after buying an additional 1,414 shares during the period. Hedge funds and other institutional investors own 86.97% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on BDX shares. Barclays cut their target price on Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating on the stock in a research note on Tuesday, June 3rd. Bank of America cut Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $190.00 price objective on the stock. in a research report on Thursday, May 1st. Stifel Nicolaus dropped their price target on Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Wells Fargo & Company boosted their price target on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an "equal weight" rating in a research report on Friday, August 8th. Finally, Raymond James Financial lowered shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research note on Friday, May 2nd. Four investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $211.44.

Becton, Dickinson and Company Stock Down 2.1%

BDX stock traded down $4.03 during trading on Thursday, hitting $191.37. 1,753,916 shares of the company's stock traded hands, compared to its average volume of 2,621,393. The firm has a market capitalization of $54.85 billion, a P/E ratio of 34.42, a PEG ratio of 1.45 and a beta of 0.20. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. The business has a fifty day simple moving average of $182.12 and a two-hundred day simple moving average of $194.78.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, beating the consensus estimate of $3.40 by $0.28. The company had revenue of $5.51 billion during the quarter, compared to the consensus estimate of $5.50 billion. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. Becton, Dickinson and Company's revenue was up 10.4% compared to the same quarter last year. During the same period last year, the firm earned $3.50 earnings per share. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Sell-side analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be paid a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a dividend yield of 2.2%. The ex-dividend date is Monday, September 8th. Becton, Dickinson and Company's payout ratio is presently 74.82%.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP David Shan sold 1,166 shares of Becton, Dickinson and Company stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $171.19, for a total transaction of $199,607.54. Following the completion of the sale, the executive vice president directly owned 4,575 shares in the company, valued at approximately $783,194.25. The trade was a 20.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Claire Fraser sold 863 shares of Becton, Dickinson and Company stock in a transaction on Friday, August 8th. The stock was sold at an average price of $192.30, for a total transaction of $165,954.90. Following the sale, the director owned 23,143 shares of the company's stock, valued at $4,450,398.90. The trade was a 3.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 3,214 shares of company stock worth $579,206. Company insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.